Dear DABS Member,
We are beyond excited to invite you to our next coffee morning in CapitalSpring, where we will be delving into a crucial topic that affects a significant portion of the population: diabetes care. And we are absolutely thrilled to have Novo Nordisk, an esteemed DABS Corporate Member, join us as our distinguished guest for this special occasion—the final coffee morning before the summer break.
Look beyond the sugar-control in Diabetes-care
Novo Nordisk is the pioneer of innovation and scientific breakthrough in the cardiometabolic therapeutic area, focusing on diabetes and obesity.
One in three Singaporean are projected to develop diabetes in their lifetime and expected to reach one million people by 20501. Obesity is one of the critical risk factor for developing diabetes. In addition, obesity is linked to over 200 other diseases2, including cardiovascular diseases, stroke, osteoarthritis, infertility in women, sleep apnoea and an increased risk of 13 different types of cancers such as liver, kidney and breast3. Optimal weight and blood sugar control are equally important for people living with diabetes in managing.
During this coffee morning, we will share a high level introduction to Novo Nordisk, our portfolio and dive into how Glucagon-like Peptide-1 (GLP-1) Receptor Agonists address most of the issues related to weight and diabetes also deemed to be protective for the heart - particularly in preventing heart attacks from blockages of the blood vessels.
Join us for an enlightening morning of coffee, knowledge-sharing, and empowerment as we look beyond sugar control and toward a holistic approach to diabetes management ☕💡
Reference:
1. https://www.straitstimes.com/singapore/pm-lee-hsien-loong-calls-on-global-community-to-work-together-in-war-against-diabetes
2. Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359
3. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at https://www.cdc.gov/media/releases/2017/p1003-vs-cancer-obesity.html
About the speakers
Elisha Whitfield, Senior Director
Elisha Whitfield is the Senior Director for Commercial Affairs and Strategy for South East Asia at Novo Nordisk. Based in Singapore, she leads a diverse and engaged team that drive the commercial strategies for the Novo Nordisk portfolio and ensure growth and frontline excellence in the Region.
Elisha is an experienced commercial leader with a track record of leading high performing teams to deliver strong launches of small molecule and biological products. Elisha has worked across multiple therapy areas, at local, regional and global levels. Prior to moving to Singapore, Elisha previously held the post of Global Commercial Vice President for Alzheimer’s Disease (AD) based in Novo Nordisk Headquarters in Denmark.
Lee Jun Seng, Senior Manager
Lee Jun Seng is the Senior Manager, Diabetes Portfolio with the Commercial Affairs and Strategy Team in Novo Nordisk Business Area South East Asia (BASEA) based in Singapore.
Jun Seng is responsible for the GLP-1 and Insulin portfolio, driving change for better patient outcomes and market leadership in diabetes through patient-focused and innovative initiatives. Prior to Novo Nordisk, he worked at various pharmaceutical MNCs in multiple therapeutic areas, such as oncology, urology, anti-infectives and etc.
Date & Time:
Monday, 12 June 2023, 8.00 - 9.00am
Venue:
Saxo Markets Singapore
88 Market Street CapitaSpring #31-01
S-048948
Registration & Cost:
The event is free of charge and for DABS members only. Registration is mandatory.
Do you want to enjoy all DABS seminars and events in 2023 for only SGD100? Sign up for DABS Membership today!
Kindly register here for the event: